Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
Read moreMedivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
Read moreQuarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.